Why the study?
Does the choice of intermediate-acting neuromuscular blocking drug affect perioperative costs in children undergoing ambulatory surgery?
Does the choice of intermediate-acting neuromuscular blocking drug affect perioperative costs in children undergoing ambulatory surgery?
Answers are grounded in this paper and cite their sources.
Cisatracurium is the least expensive intermediate-acting neuromuscular drug for maintenance infusion in pediatric ambulatory surgery.
The purpose of this investigation was to compare the costs of intermediate-acting neuromuscular blocking drugs in children during routine ambulatory surgery. We studied 200 healthy, 2–10-yr-old children undergoing elective dental restorative surgery. During Part 1 of the study, children received an inhaled anesthetic with halothane and nitrous oxide, whereas in Part 2, the anesthetic was IV propofol with nitrous oxide. The study drugs were atracurium, cisatracurium, mivacurium, rocuronium, and vecuronium. Patients were initially administered 2× the effective dose for 95% of the study drug. After recovery to 10% of baseline neuromuscular function, the neuromuscular blockade was rigidly maintained with an infusion of the study drug at about 10% of baseline function. Neuromuscular drug costs were approximated as drug usage × cost/unit. The initial drug costs were not substantially different for both Parts 1 and 2, but over time, mivacurium became the most expensive drug and cisatracurium the least expensive. In conclusion, based on current costs, cisatracurium is the least expensive intermediate-acting neuromuscular drug.
No takes yet. Share an insight, caveat, or question.
Splinter et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: